Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

Lignende værker

• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  af: Pao, William, et al.
  Udgivet: (2005)
• Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors
  af: Politi, Katerina, et al.
  Udgivet: (2006)
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  af: Pao, William, et al.
  Udgivet: (2005)
• Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
  af: Janjigian, Yelena Y., et al.
  Udgivet: (2011)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  af: Zakowski, Maureen F., et al.
  Udgivet: (2009)